BioDlink International Company Limited (traded in Hong Kong as BIODLINK-B) reported no movements in its share capital for the month ended 30 June 2026.

The number of issued ordinary shares remained unchanged at 772.79 million, with no treasury shares held or cancelled. The company reconfirmed that at least 25% of its issued share capital is in public hands, in line with Main Board Rule 13.32B.

Options activity was minimal. Under the 2013 Pre-IPO Share Option Scheme, 20,000 options were outstanding at month-end, identical to the prior month. No options were granted, exercised, lapsed or cancelled, and consequently no new shares were issued and no proceeds were raised.

There were no warrants, convertible securities or other arrangements affecting the share count, and no Hong Kong Depositary Receipts were outstanding.

All confirmations required under Main Board Rule 13.25C were provided by Joint Company Secretary Christopher Lui, indicating full regulatory compliance during the reporting period.